Equillium Results Presentation Deck

Assessment of PK/PD and Anti-Drug Antibodies • PK profile at 1.6 mg/kg comparable between Type A and B patients ● Reduction of cell surface CD6 (PD marker) is consistent with the mechanism of action • To date, no subjects exhibited high titers of ADA, no changes to PK in ADA positive subjects equillium Mean +/- SD itolizumab concentration (ng/mL) 10000- 100- PK similar between Type A and B subjects Based on interim data from 2 Sep 2022-subject to change: Putterman et al., PO1623, ASN 2021 Abbreviations: ADA: anti-drug antibody: PD: pharmacodynamic: PK: Pharmacokinetic 15 Study day Type A 0.4 mg/kg Type A 0.8 mg/kg Type A 1.6 mg/kg Type A 2.4 mg/kg Type A 3.2 mg/kg Type B 1.6 mg/kg 29 25

View entire presentation